Search the Newsreel

CSTL (CSTL) files notice to sell 24,908 common shares on NASDAQ

A holder of CSTL common stock has filed a notice of intent to sell up to 24,908 shares on NASDAQ through Morgan Stanley Smith Barney LLC Executive Financial Services. The indicated aggregate market value of these shares is $741,493.72, and they originated from restricted …

Insider Buying: Angel Studios (NYSE:ANGX) Director Purchases 246,153 Shares of Stock

Assembly Biosciences (ASMB) Stock Jumps As Losses Shrink And Revenue Builds

Vertiqal Studios Grows Revenue, Narrows Loss and Adds Veteran Media Executive to Board

MCDONALDS CORP (MCD) president Anderson Skye details options, PRSUs and stock

Twist Bioscience Corp (TWST) Stock Down 5.4% but Still Overvalued -- GF Score: 69/100

Twist Bioscience Corp (TWST) shares dropped by 5.4% to $118.57, yet the stock is considered 126.4% overvalued compared to its GF Value™ of $52.38. Despite a strong growth rank of 10/10, the company's profitability and valuation ranks are low, coupled with significant insider selling …

Media Executive Jay Kovitz Joins Vertiqal Studios Board

Satellos Bioscience Sets Up US$50 Million U.S. At-the-Market Share Sales Facility

Inhibrx Biosciences (INBX) holders disclose 1.49M-share, 9.99% position

Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have reported a beneficial ownership of 1,489,443 shares of Inhibrx Biosciences, Inc. (INBX) common stock, representing 9.99% of the class. This stake includes common shares and pre-funded warrants, with the exercise of …

Spruce Biosciences (SPRB): ADAR1, Schneeberger disclose 2.5% beneficial stake

ADAR1 Capital Management, LLC and Daniel Schneeberger have disclosed a 2.5% beneficial ownership stake in Spruce Biosciences, Inc. (SPRB) through a SCHEDULE 13G/A filing. This stake, totaling 67,717 shares, is held across various managed accounts, with both parties exercising shared voting and dispositive power. …

TYRA Biosciences (TYRA) holder reports 3.55M-share, 6% beneficial stake

Assembly Biosciences (ASMB) sees Paradigm BioCapital report 7.8% ownership stake

Paradigm BioCapital, along with its related entities and Senai Asefaw, M.D., has reported a collective beneficial ownership of 7.8% in Assembly Biosciences (ASMB), totaling 1,553,748 shares. This stake is based on an amended Schedule 13G filing, with Paradigm BioCapital International Fund Ltd. directly holding …

Twist Bioscience (TWST) director sells 2,240 shares to cover RSU tax

Twist Bioscience director Katryn Blake sold 2,240 shares of common stock on August 12, 2026, at $122.88 per share. This transaction was not a discretionary trade but was executed to cover tax liabilities arising from the vesting of Restricted Stock Units. Following the sale, …

Angel Studios (ANGX) CEO Neal Harmon purchases 29K shares in open-market trade

Angel Studios CEO Neal Harmon purchased 29,035.659 shares of Class A Common Stock on August 13, 2026, in an open-market transaction. The shares were bought at a weighted average price of $4.3053, with individual trades ranging from $4.2650 to $4.3400 per share. Following this …

Frazier funds disclose Aura Biosciences (AURA) stake and 9.99% warrant cap

A Schedule 13G/A filing indicates that Frazier Life Sciences-affiliated funds and individuals have updated their ownership report for Aura Biosciences (AURA). Frazier Life Sciences Public Fund, L.P. directly holds 5.6% of Aura Biosciences' common stock, and other Frazier funds also hold significant shares. The …

Solid Biosciences (SLDB): Vestal Point Capital discloses 4.8% ownership, including warrant shares

Vestal Point Capital, along with its Chief Investment Officer Ryan Wilder, has reported a beneficial ownership of 4.8% in Solid Biosciences Inc. (SLDB). This stake includes 4,833,796 common shares, of which 2,673,796 are issuable upon the exercise of pre-funded common stock purchase warrants. The …

Caribou Biosciences, Inc. (NASDAQ:CRBU) Receives Consensus Rating of "Moderate Buy" from Analysts

Caribou Biosciences (NASDAQ:CRBU) has received a consensus "Moderate Buy" rating from analysts, with an average 12-month price target of $7.75. The company's shares recently traded down 2.2% to $1.57. Caribou Biosciences reported a narrower-than-expected quarterly loss but missed revenue estimates, and institutional investors own …

Caribou Biosciences earnings beat by $0.07, revenue topped estimates

Caribou Biosciences (NASDAQ: CRBU) reported second-quarter EPS of $-0.240, beating analyst estimates by $0.07, and revenue of $2.65 million, surpassing the consensus estimate of $2.3 million. Despite the earnings beat, the company's stock price has declined by -24.770% in the last three months and …

Satellos Bioscience (MSLE) enters $50M at-the-market share deal

Gujarat Themis Biosyn Q1FY27 profit rises 22%, EBITDA margin hits 47.5%

Satellos Bioscience Inc. Stock 12‑Month Price Target Cut to $21.78, Implies 122% Upside

Satellos Bioscience Inc.'s average 12-month price target has been adjusted to $21.78, down from $22.04, according to estimates from 6 analysts. This new target suggests a potential upside of approximately 122% from the August 13 closing price. The consensus rating among 7 covering analysts …

Schonfeld Strategic Advisors (INBX) discloses 5.33% Inhibrx Biosciences stake in 13G filing

Schonfeld Strategic Advisors LLC has disclosed a 5.33% beneficial ownership stake in Inhibrx Biosciences, Inc. (INBX) through a Schedule 13G filing. This amounts to 781,678 shares of common stock, representing 5.33% of the 14,671,186 shares outstanding as of May 8, 2026. Schonfeld maintains sole …

Cellectar Biosciences (CLRB): Caligan Partners reports 5.9% ownership stake

Caligan Partners LP and David Johnson have reported a beneficial ownership stake of 5.9% in Cellectar Biosciences (CLRB), amounting to 469,998 shares. This ownership is held through Caligan-managed funds and accounts, with shared voting and dispositive power. The percentage is based on 7,991,812 shares …

Senti Biosciences Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Senti Biosciences Holdings, Inc. reported its earnings results for the second quarter and six months ended June 30, 2026. For the second quarter, the company's net loss decreased to USD 12.75 million from USD 14.73 million a year prior, with basic and diluted loss …

Why (ASMB) Price Action Is Critical for Tactical Trading

This article analyzes the price action of Assembly Biosciences Inc. (ASMB), highlighting a mid-channel oscillation pattern and a strong risk-reward short setup. It presents three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored for different risk profiles, along with multi-timeframe signal analysis to …

Baker Bros. Advisors (IDYA) reports 5.2% IDEAYA stake and capped warrants

Baker Bros. Advisors and its related entities have disclosed a 5.2% beneficial ownership stake in IDEAYA Biosciences, Inc. (IDYA), totaling 5,010,030 shares based on 96,375,637 shares outstanding as of June 30, 2026. The firm also holds prefunded warrants with a low exercise price but …

ARK reports 9.59% stake in Pacific Biosciences (PACB)

ARK Investment Management LLC and Catherine D. Wood have reported a beneficial ownership of 9.59% in Pacific Biosciences of California, Inc. (PACB), amounting to 29,781,416 shares. This disclosure, made via a SCHEDULE 13G/A filing, details their sole and shared voting and dispositive powers over …

American Century group reports 5.4% Emergent BioSolutions (EBS) ownership on Schedule 13G

American Century ETF Trust and its affiliates, including American Century Investment Management, Inc., American Century Companies, Inc., and the Stowers Institute for Medical Research, have reported passive ownership stakes in Emergent BioSolutions Inc. (EBS) common stock via a Schedule 13G filing. The ETF Trust …

Assembly Biosciences (NASDAQ:ASMB) Trading Up 8.2% on Strong Earnings

Assembly Biosciences (NASDAQ:ASMB) saw its shares rise by 8.2% after reporting better-than-expected quarterly earnings, with a loss of $0.20 per share against an anticipated $0.72 loss and revenue of $13.37 million surpassing estimates of $8.60 million. Analysts have a "Moderate Buy" consensus rating with …

Twist Bioscience (TWST): ARK Investment Management reports 4.55M-share, 7.31% stake

ARK Investment Management LLC and its founder Catherine D. Wood have reported a beneficial ownership of 4,549,803 shares of Twist Bioscience Corp (TWST) common stock, representing 7.31% of the company's class. The filing, a Schedule 13G/A, indicates that ARK has sole voting power over …

Spruce Biosciences (SPRB) sees AWM Investment disclose 5.1% equity stake

Bright Minds Biosciences (DRUG): Cormorant Asset Management reports 9.17% ownership stake

Cormorant Asset Management, LP and Bihua Chen have reported a significant ownership stake of 9.17% in Bright Minds Biosciences Inc. This beneficial ownership translates to 900,000 Common Shares out of 9,812,061 shares outstanding as of May 15, 2026. The reporting persons share voting and …

Daré Bioscience Announces $6.0 Million Registered Direct Offering and Concurrent Private Placement

Daré Bioscience has announced a definitive securities purchase agreement with institutional investors for a registered direct offering, expecting to raise approximately $6.0 million. The offering includes the sale of about 4.38 million shares of common stock at $1.37 per share, along with concurrent private …

Winking Studios Limited Reports Earnings Results for the Half Year Ended June 30, 2026

Citi Maintains Caribou Biosciences(CRBU.US) With Buy Rating, Maintains Target Price $8

Citi has reiterated its Buy rating for Caribou Biosciences (CRBU.US) and maintained its target price at $8. This indicates the firm's continued positive outlook on the company's stock performance.

Cellectar Biosciences (CLRB) investor discloses 9.99% stake and warrant holdings

SilverArc Capital Management, LLC and Devesh Gandhi have reported a beneficial ownership of 9.99% in Cellectar Biosciences Inc. Class A Common Stock, totaling 851,285 shares. This disclosure, made via a SCHEDULE 13G SEC filing, indicates shared voting and dispositive power over these shares. The …